I like to get this clarified. My understanding is Grandcimab is not such a game changer. I think CSL already has products in the market and therefore there will be some loss of income from those. I have seen $50 being mentioned and that is a just an estimate of the value of R&D budget CSL keeps spending. Try to monetise. I am sure someone in this group can confirm which is correct.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$257.38 |
Change
8.990(3.62%) |
Mkt cap ! $124.6B | |||
| Open | High | Low | Value | Volume |
| $252.00 | $258.31 | $251.10 | $370.9M | 1.440M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 90 | $257.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $257.38 | 3331 | 1 |
View Market Depth
| Last trade - 16.11pm 18/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |